Elon Musk (Bill Clark/CQ Roll Call via AP Images)
September 20, 2023 01:36 PM EDT
R&D
Pharma
FDA+

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Nicole DeFeudis

Editor

Elon Musk’s brain-com­put­er in­ter­face start­up is of­fi­cial­ly re­cruit­ing paral­y­sis pa­tients for its first in-hu­man tri­al.

Neu­ralink an­nounced Tues­day that it has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times